Group B streptococcus; Streptococcus agalactiae; Neonatal infection; Early-onset disease; Late-onset disease; Group B streptococcal vaccine
Abstract :
[en] PURPOSE
Group B streptococcus (GBS) remains a leading cause of invasive disease, mainly sepsis and meningitis, in infants < 3 months of age and of mortality among neonates. This study, a major component of the European DEVANI project (Design of a Vaccine Against Neonatal Infections) describes clinical and important microbiological characteristics of neonatal GBS diseases. It quantifies the rate of antenatal screening and intrapartum antibiotic prophylaxis among cases and identifies risk factors associated with an adverse outcome.
METHODS
Clinical and microbiological data from 153 invasive neonatal cases (82 early-onset [EOD], 71 late-onset disease [LOD] cases) were collected in eight European countries from mid-2008 to end-2010.
RESULTS
Respiratory distress was the most frequent clinical sign at onset of EOD, while meningitis is found in > 30% of LOD. The study revealed that 59% of mothers of EOD cases had not received antenatal screening, whilst GBS was detected in 48.5% of screened cases. Meningitis was associated with an adverse outcome in LOD cases, while prematurity and the presence of cardiocirculatory symptoms were associated with an adverse outcome in EOD cases. Capsular-polysaccharide type III was the most frequent in both EOD and LOD cases with regional differences in the clonal complex distribution.
CONCLUSIONS
Standardizing recommendations related to neonatal GBS disease and increasing compliance might improve clinical care and the prevention of GBS EOD. But even full adherence to antenatal screening would miss a relevant number of EOD cases, thus, the most promising prophylactic approach against GBS EOD and LOD would be a vaccine for maternal immunization.
Research Center/Unit :
CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège GSK (formal Novartis) vaccine research, Siena, Italy National Reference Center Streptococcus agalactiae of Belgium - CHULiege
Disciplines :
Microbiology Pediatrics Immunology & infectious disease Reproductive medicine (gynecology, andrology, obstetrics) Laboratory medicine & medical technology Public health, health care sciences & services
Author, co-author :
Lohrmann, Florens; University of Freiburg, Germany
Hufnagel Markus; University of Freiburg, Germany
Kunze, Mirjam; University of Freiburg, Germany
Afshar Baharak; UK Health Security Agency GB, London UK
Creti, Roberta; Istituto Superiore Di Sanita, Roma, Italy
Detcheva, Antoaneta; National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria
Kosakova, Jana; National Institute of Public Health, Prague, Czech Republik
Rodriguez-Granger, Javier; Hospital Universitario Virgen de Las Nieves, Granada, Spain
Skov Sorensen, Uffe B.; AU - Aarhus University [DK]
Margarit, Immaculada; GSK Vaccines, Siena, Italy
Maione, Domenico; GSK Vaccines, Siena, Italy
Rinaudo, Daniela; GSK Vaccines, Siena, Italy
Orefici, Graziella; Istituto Superiore Di Sanita, Roma, Italy
Telford, John; GSK Vaccines, Siena, Italy
de la Rosa Fraile, Manuel; Hospital Universitario Virgen de Las Nieves, Granada, Spain
Kilian, Mogens; AU - Aarhus Universitet [DK]
Efstratiou, Androulla; UK Health Security Agency GB, London UK
Berner, Reinhard ✱; University Hospital Carl Gustav Carus, Dresden, Germany
Melin, Pierrette ✱; Université de Liège - ULiège > Département des sciences biomédicales et précliniques ; Centre Hospitalier Universitaire de Liège - CHU > > Service de microbiologie clinique ; The DEVANI Study Group
Seale AC, Bianchi-Jassir F, Russell NJ, Kohli-Lynch M, Tann CJ, Hall J, Madrid L, Blencowe H, Cousens S, Baker CJ, Bartlett L, Cutland C, Gravett MG, Heath PT, Ip M, Le Doare K, Madhi SA, Rubens CE, Saha SK, Schrag SJ, Sobanjo-Ter Meulen A, Vekemans J, Lawn JE. Estimates of the burden of group B streptococcal disease worldwide for pregnant women, stillbirths, and children. Clin Infect Dis. 2017;65:S200–19.
Baker CJ, Barrett FF, Gordon RC, Yow MD. Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants. J Pediatr. 1973;82:724–9.
Baker CJ. The spectrum of perinatal group B streptococcal disease. Vaccine. 2013;31(Suppl 4):D3-6.
Heath PT, Schuchat A. Perinatal group B streptococcal disease. Best Pract Res Clin Obstet Gynaecol. 2007;21:411–24.
Joubrel C, Tazi A, Six A, Dmytruk N, Touak G, Bidet P, Raymond J, Trieu Cuot P, Fouet A, Kernéis S, Poyart C. Group B streptococcus neonatal invasive infections, France 2007–2012. Clin Microbiol Infect. 2015;21:910–6.
Tazi A, Plainvert C, Anselem O, Ballon M, Marcou V, Seco A, El Alaoui F, Joubrel C, El Helali N, Falloukh E, Frigo A, Raymond J, Trieu-Cuot P, Branger C, Le Monnier A, Azria E, Ancel P-Y, Jarreau PH, Mandelbrot L, Goffinet F, Poyart C. Risk factors for infant colonization by hypervirulent CC17 group B streptococcus: toward the understanding of late-onset disease. Clin Infect Dis. 2019;69:1740–8.
Madrid L, Seale AC, Kohli-Lynch M, Edmond KM, Lawn JE, Heath PT, Madhi SA, Baker CJ, Bartlett L, Cutland C, Gravett MG, Ip M, Le Doare K, Rubens CE, Saha SK, Sobanjo-Ter Meulen A, Vekemans J, Schrag S, Infant GBS Disease Investigator Group. Infant group B streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses. Clin Infect Dis. 2017;65:S160–72.
Dagnew AF, Cunnington MC, Dube Q, Edwards MS, French N, Heyderman RS, Madhi SA, Slobod K, Clemens SAC. Variation in reported neonatal group B streptococcal disease incidence in developing countries. Clin Infect Dis. 2012;55:91–102.
Bekker V, Bijlsma MW, van de Beek D, Kuijpers TW, van der Ende A. Incidence of invasive group B streptococcal disease and pathogen genotype distribution in newborn babies in the Netherlands over 25 years: a nationwide surveillance study. Lancet Infect Dis. 2014;14:1083–9.
Berardi A, Baroni L, BacchiReggiani ML, Ambretti S, Biasucci G, Bolognesi S, Capretti MG, Carretto E, Ciccia M, Fiorini V, Fortini C, Gargano G, Pedna MF, Rizzo V, Creti R, Ferrari F, GBS Prevention Working Group Emilia-Romagna. The burden of early-onset sepsis in Emilia-Romagna (Italy): a 4-year, population-based study. J Matern-Fetal Neonatal Med. 2016;29:3126–31.
Lamagni TL, Keshishian C, Efstratiou A, Guy R, Henderson KL, Broughton K, Sheridan E. Emerging trends in the epidemiology of invasive group B streptococcal disease in England and Wales, 1991–2010. Clin Infect Dis. 2013;57:682–8.
Di Renzo GC, Melin P, Berardi A, Blennow M, Carbonell-Estrany X, Donzelli GP, Hakansson S, Hod M, Hughes R, Kurtzer M, Poyart C, Shinwell E, Stray-Pedersen B, Wielgos M, El Helali N. Intrapartum GBS screening and antibiotic prophylaxis: a European consensus conference. J Matern Fetal Neonatal Med. 2015;28:766–82.
Kobayashi M, Vekemans J, Baker CJ, Ratner AJ, Le Doare K, Schrag SJ. Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries. F1000Research. 2016;5:2355.
Shabayek S, Spellerberg B. Group B streptococcal colonization, molecular characteristics, and epidemiology. Front Microbiol. 2018;9:437.
Remington JS, Wilson CB, Nizet V, Klein JO, Maldonado Y. Infectious diseases of the fetus and newborn E-book. Amsterdam: Elsevier Health Sciences; 2010.
Sørensen UBS, Klaas IC, Boes J, Farre M. The distribution of clones of Streptococcus agalactiae (group B streptococci) among herdspersons and dairy cows demonstrates lack of host specificity for some lineages. Vet Microbiol. 2019;235:71–9.
Plainvert C, Hays C, Touak G, Joubrel-Guyot C, Dmytruk N, Frigo A, Poyart C, Tazi A. Multidrug-resistant hypervirulent group B streptococcus in neonatal invasive infections, France, 2007–2019. Emerg Infect Dis. 2020;26:2721–4.
Jones N, Bohnsack JF, Takahashi S, Oliver KA, Chan M-S, Kunst F, Glaser P, Rusniok C, Crook DWM, Harding RM, Bisharat N, Spratt BG. Multilocus sequence typing system for group B streptococcus. J Clin Microbiol. 2003;41:2530–6.
Sørensen UBS, Poulsen K, Ghezzo C, Margarit I, Kilian M. Emergence and global dissemination of host-specific Streptococcus agalactiae clones. MBio. 2010;1:2.
McGee L, Chochua S, Li Z, Mathis S, Rivers J, Metcalf B, Ryan A, Alden N, Farley MM, Harrison LH, Snippes Vagnone P, Lynfield R, Smelser C, Muse A, Thomas AR, Schrag S, Beall BW. Multistate, population-based distributions of candidate vaccine targets, clonal complexes, and resistance features of invasive group B streptococci within the United States, 2015–2017. Clin Infect Dis. 2021;72:1004–13.
Hayes K, O’Halloran F, Cotter L. A review of antibiotic resistance in group B Streptococcus: the story so far. Crit Rev Microbiol. 2020;46:253–69.
Castor ML, Whitney CG, Como-Sabetti K, Facklam RR, Ferrieri P, Bartkus JM, Juni BA, Cieslak PR, Farley MM, Dumas NB. Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol. 2008;2:2.
Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine. 2003;21:3468–72.
Davies HG, Carreras-Abad C, Le Doare K, Heath PT. Group B streptococcus: trials and tribulations. Pediatr Infect Dis J. 2019;38:S72.
Carreras-Abad C, Ramkhelawon L, Heath PT, Le Doare K. A vaccine against group B streptococcus: recent advances. Infect Drug Resist. 2020;13:1263–72.
Bianchi-Jassir F, Paul P, To K-N, Carreras-Abad C, Seale AC, Jauneikaite E, Madhi SA, Russell NJ, Hall J, Madrid L, Bassat Q, Kwatra G, Le Doare K, Lawn JE. Systematic review of Group B Streptococcal capsular types, sequence types and surface proteins as potential vaccine candidates. Vaccine. 2020;38:6682–94.
Doare KL, Kampmann B, Vekemans J, Heath PT, Goldblatt D, Nahm MH, Baker C, Edwards MS, Kwatra G, Andrews N, Madhi SA, ter Meulen AS, Anderson AS, Corsaro B, Fischer P, Gorringe A. Serocorrelates of protection against infant group B streptococcus disease. Lancet Infect Dis. 2019;19:e162–71.
Fabbrini M, Rigat F, Rinaudo CD, Passalaqua I, Khacheh S, Creti R, Baldassarri L, Carboni F, Anderloni G, Rosini R, Maione D, Grandi G, Telford JL, Margarit I. The protective value of maternal group B Streptococcus antibodies: quantitative and functional analysis of naturally acquired responses to capsular polysaccharides and pilus proteins in European maternal sera. Clin Infect Dis. 2016;63:746–53.
Rodriguez-Granger J, Alvargonzalez JC, Berardi A, Berner R, Kunze M, Hufnagel M, Melin P, Decheva A, Orefici G, Poyart C, Telford J, Efstratiou A, Killian M, Krizova P, Baldassarri L, Spellerberg B, Puertas A, Rosa-Fraile M. Prevention of group B streptococcal neonatal disease revisited. The DEVANI European project. Eur J Clin Microbiol Infect Dis. 2012;31:2097–104.
Afshar B, Broughton K, Creti R, Decheva A, Hufnagel M, Kriz P, Lambertsen L, Lovgren M, Melin P, Orefici G, Poyart C, Radtke A, Rodriguez-Granger J, Sørensen UBS, Telford J, Valinsky L, Zachariadou L, Members of the DEVANI Study Group, Efstratiou A. International external quality assurance for laboratory identification and typing of Streptococcus agalactiae (Group B streptococci). J Clin Microbiol. 2011;49:1475–82.
Yao K, Poulsen K, Maione D, Rinaudo CD, Baldassarri L, Telford JL, Sorensen UBS, Members of the DEVANI Study Group, Kilian M. Capsular gene typing of streptococcus agalactiae compared to serotyping by latex agglutination. J Clin Microbiol. 2013;51:503–7.
Imperi M, Pataracchia M, Alfarone G, Baldassarri L, Orefici G, Creti R. A multiplex PCR assay for the direct identification of the capsular type (Ia to IX) of Streptococcus agalactiae. J Microbiol Methods. 2010;80:212–4.
Poyart C, Tazi A, Réglier-Poupet H, Billoët A, Tavares N, Raymond J, Trieu-Cuot P. Multiplex PCR assay for rapid and accurate capsular typing of group B streptococci. J Clin Microbiol. 2007;45:1985–8.
Kong F, Lambertsen LM, Slotved H-C, Ko D, Wang H, Gilbert GL. Use of phenotypic and molecular serotype identification methods to characterize previously nonserotypeable group B streptococci. J Clin Microbiol. 2008;46:2745–50.
Berardi A, Cattelani C, Creti R, Berner R, Pietrangiolillo Z, Margarit I, Maione D, Ferrari F. Group B streptococcal infections in the newborn infant and the potential value of maternal vaccination. Expert Rev Anti Infect Ther. 2015;13:1387–99.
Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine. 2013;31(Suppl 4):D20-26.
Pulver LS, Hopfenbeck MM, Young PC, Stoddard GJ, Korgenski K, Daly J, Byington CL. Continued early onset group B streptococcal infections in the era of intrapartum prophylaxis. J Perinatol Off J Calif Perinat Assoc. 2009;29:20–5.
Stoll BJ, Hansen NI, Sánchez PJ, Faix RG, Poindexter BB, Van Meurs KP, Bizzarro MJ, Goldberg RN, Frantz ID, Hale EC, Shankaran S, Kennedy K, Carlo WA, Watterberg KL, Bell EF, Walsh MC, Schibler K, Laptook AR, Shane AL, Schrag SJ, Das A, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics. 2011;127:817–26.
Benitz WE, Gould JB, Druzin ML. Risk factors for early-onset group B streptococcal sepsis: estimation of odds ratios by critical literature review. Pediatrics. 1999;103:e77–e77.
Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease–revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59:1–36.
Romain A-S, Cohen R, Plainvert C, Joubrel C, Béchet S, Perret A, Tazi A, Poyart C, Levy C. Clinical and laboratory features of group B streptococcus meningitis in infants and newborns: study of 848 cases in France, 2001–2014. Clin Infect Dis. 2018;66:857–64.
Ji W, Liu H, Madhi SA, Cunnington M, Zhang Z, Dangor Z, Zhou H, Mu X, Jin Z, Wang A, Qin X, Gao C, Zhu Y, Feng X, She S, Yang S, Liu J, Lei J, Jiang L, Liu Z, Li G, Li Q, Deng Q, Gao K, Fang Y. Clinical and molecular epidemiology of invasive group B streptococcus disease among infants, China. Emerg Infect Dis. 2019;25:2021–30.
Berardi A, Rossi C, Lugli L, Creti R, BacchiReggiani ML, Lanari M, Memo L, Pedna MF, Venturelli C, Perrone E, Ciccia M, Tridapalli E, Piepoli M, Contiero R, Ferrari F. Group B streptococcus late-onset disease: 2003–2010. Pediatrics. 2013;131:e361-368.
Regan JA, Klebanoff MA, Nugent RP, Eschenbach DA, Blackwelder WC, Lou Y, Gibbs RS, Rettig PJ, Martin DH, Edelman R. Colonization with group B streptococci in pregnancy and adverse outcome. VIP Study Group. Am J Obstet Gynecol. 1996;174:1354–60.
Fluegge K, Siedler A, Heinrich B, Schulte-Moenting J, Moennig M-J, Bartels DB, Dammann O, von Kries R, Berner R, German Pediatric Surveillance Unit Study Group. Incidence and clinical presentation of invasive neonatal group B streptococcal infections in Germany. Pediatrics. 2006;117:e1139-1145.
Libster R, Edwards KM, Levent F, Edwards MS, Rench MA, Castagnini LA, Cooper T, Sparks RC, Baker CJ, Shah PE. Long-term outcomes of group B streptococcal meningitis. Pediatrics. 2012;130:e8–15.
